Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Cost of Revenue over the past 5 years, most recently at $635994.0 for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 2.28% year-over-year to $635994.0; the TTM value through Dec 2025 reached $3.2 million, up 1.43%, while the annual FY2025 figure was $3.2 million, 7.46% down from the prior year.
  • Cost of Revenue for Q4 2025 was $635994.0 at InMed Pharmaceuticals, down from $716962.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $1.3 million in Q2 2023 and troughed at $127308.0 in Q1 2022.
  • A 5-year average of $668484.4 and a median of $728056.0 in 2025 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: surged 560.93% in 2023 and later tumbled 37.99% in 2024.
  • Year by year, Cost of Revenue stood at $153537.0 in 2021, then soared by 120.55% to $338620.0 in 2022, then soared by 170.53% to $916058.0 in 2023, then dropped by 28.96% to $650813.0 in 2024, then decreased by 2.28% to $635994.0 in 2025.
  • Business Quant data shows Cost of Revenue for INM at $635994.0 in Q4 2025, $716962.0 in Q3 2025, and $728056.0 in Q2 2025.